Answers are grounded in this paper and cite their sources.
In this study, we observed an increased risk of CVDs associated with glucocorticoid dose intake even at lower doses (<5 mg) in 6 immune-mediated diseases. These results highlight the importance of prompt and regular monitoring of cardiovascular risk and use of primary prevention treatment at all glucocorticoid doses.
No takes yet. Share an insight, caveat, or question.
Pujades‐Rodríguez et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: